Evidence map›Paper›PMID 29778981›Full record

ReviewBiomaterials2018

Walking the line: The fate of nanomaterials at biological barriers.

Huan Meng, Wei Leong, Kam W Leong, Chunying Chen, Yuliang Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Nanozymes for Accelerating the Foot Wound Healing: A Review.International journal of nanomedicine · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huan MengCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Department of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA. Electronic address: hmeng@mednet.ucla.edu.
Wei LeongDepartment of Biomedical Engineering, Columbia University, New York, NY 10025, USA.
Kam W LeongDepartment of Biomedical Engineering, Columbia University, New York, NY 10025, USA.
Chunying ChenCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
Yuliang ZhaoCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing 100190, China; Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China. Electronic address: zhaoyl@nanoctr.cn.

Funding

UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

Biological systems have developed an efficient multi-tiered defense system to block foreign substances such as engineered nanomaterials (NMs) from causing damage. In a pathological scenario, the disease itself may also pose additional barriers due to the imbalance between abnormal cells and their surrounding microenvironment, and NMs could behave similarly or differently to classic foreign substances, depending on their unique characteristics. Thus, understanding the mechanisms that govern the fate of NMs against these biological barriers, including the strategies that can be used to shift their fate between access and blockage, become key information for NMs design. In this manuscript, we first describe the biological barriers that NMs may encounter, and further discuss how these biological barrier interactions could shift the fate of NMs between toxicity and therapeutic potential. A list of effects that may influence NMs access at nano/bio interface are presented and discussed, followed by personal insights on the important nano/bio topics that require additional research for a better understanding of NM/biological barrier interactions.

Indexed as

AnimalsBiocompatible MaterialsBiological TransportHumansNanomedicineNanoparticlesNanotechnologyPermeabilityProtein BindingSolubilitySurface PropertiesBiocompatible MaterialsBiological barriersNano/bio interfaceNanomaterialsNanomedicineNanosafety

Identifiers

PMID29778981
PMCPMC5984195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.